AP2004003050A0 - Chemically modified human growth hormone conjugates - Google Patents
Chemically modified human growth hormone conjugatesInfo
- Publication number
- AP2004003050A0 AP2004003050A0 APAP/P/2004/003050A AP2004003050A AP2004003050A0 AP 2004003050 A0 AP2004003050 A0 AP 2004003050A0 AP 2004003050 A AP2004003050 A AP 2004003050A AP 2004003050 A0 AP2004003050 A0 AP 2004003050A0
- Authority
- AP
- ARIPO
- Prior art keywords
- chemically modified
- growth hormone
- human growth
- modified human
- hgh
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33190701P | 2001-11-20 | 2001-11-20 | |
| PCT/US2002/037270 WO2003044056A2 (en) | 2001-11-20 | 2002-11-20 | Chemically-modified human growth hormone conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2004003050A0 true AP2004003050A0 (en) | 2004-06-30 |
Family
ID=23295870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2004/003050A AP2004003050A0 (en) | 2001-11-20 | 2002-11-20 | Chemically modified human growth hormone conjugates |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1453859A2 (es) |
| JP (2) | JP2005525302A (es) |
| KR (2) | KR20050044858A (es) |
| CN (1) | CN1608079A (es) |
| AP (1) | AP2004003050A0 (es) |
| AU (1) | AU2002356990A1 (es) |
| BR (1) | BR0214451A (es) |
| CA (1) | CA2467731A1 (es) |
| CO (1) | CO5580794A2 (es) |
| EA (2) | EA008505B1 (es) |
| EC (1) | ECSP045114A (es) |
| GE (1) | GEP20063860B (es) |
| HR (1) | HRP20040448A2 (es) |
| HU (1) | HUP0500997A2 (es) |
| IL (1) | IL162031A0 (es) |
| IS (1) | IS7268A (es) |
| MA (1) | MA27544A1 (es) |
| MX (1) | MXPA04004809A (es) |
| NO (1) | NO20042182L (es) |
| OA (1) | OA13063A (es) |
| PL (1) | PL374354A1 (es) |
| RS (1) | RS53104A (es) |
| TN (1) | TNSN04090A1 (es) |
| WO (1) | WO2003044056A2 (es) |
| ZA (1) | ZA200403907B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| WO2003049699A2 (en) * | 2001-12-11 | 2003-06-19 | Sun Bio, Inc. | Novel monofunctional polyethylene glycol aldehydes |
| US6956135B2 (en) | 2001-12-11 | 2005-10-18 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| US6916962B2 (en) | 2001-12-11 | 2005-07-12 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| US7041855B2 (en) | 2001-12-11 | 2006-05-09 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| CN101700401B (zh) * | 2002-01-18 | 2013-08-14 | 比奥根艾迪克Ma公司 | 具有用于共轭生物活性化合物的部分的聚亚烷基二醇 |
| EP1591467A1 (en) * | 2002-09-09 | 2005-11-02 | Nektar Therapeutics Al, Corporation | Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone |
| NZ538624A (en) | 2002-09-09 | 2007-01-26 | Nektar Therapeutics Al Corp | Water-soluble polymer alkanals |
| US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
| US20050281778A1 (en) * | 2003-03-28 | 2005-12-22 | Myung-Ok Park | Human growth hormone conjugated with biocompatible polymer |
| JP2007508250A (ja) * | 2003-10-10 | 2007-04-05 | ノボ ノルディスク アクティーゼルスカブ | 持続性放出製剤における長期作用性分子 |
| US7524813B2 (en) | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
| CN103215328B (zh) * | 2004-01-21 | 2016-08-03 | 诺和诺德医疗保健公司 | 转谷氨酰胺酶介导的肽的接合 |
| CN101010105A (zh) * | 2004-08-31 | 2007-08-01 | 法玛西雅厄普约翰有限责任公司 | 甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法 |
| BRPI0519430A2 (pt) | 2004-12-22 | 2009-02-10 | Ambrx Inc | hormânio do crescimento humano modificado |
| WO2006069246A2 (en) | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| AU2005323106B2 (en) * | 2004-12-22 | 2010-07-29 | Ambrx, Inc. | Methods for expression and purification of recombinant human growth hormone |
| US20090105134A1 (en) | 2005-02-10 | 2009-04-23 | Novo Nordisk A/S | C-Terminally Pegylated Growth Hormones |
| EP2360181B1 (en) | 2005-04-18 | 2013-09-18 | Novo Nordisk A/S | IL-21 variants |
| CA2620638A1 (en) | 2005-08-30 | 2007-03-08 | Novo Nordisk Health Care Ag | Liquid formulations of pegylated growth hormone |
| PL1954710T3 (pl) * | 2005-11-08 | 2011-09-30 | Ambrx Inc | Przyspieszacze do modyfikacji aminokwasów niewystępujących w przyrodzie i polipeptydów zbudowanych z aminokwasów nie występujących w przyrodzie |
| JP2009519942A (ja) * | 2005-12-14 | 2009-05-21 | アンブルックス，インコーポレイテッド | 非天然アミノ酸およびポリペプチドを含んでいる組成物、それらに関する方法、ならびに、それらの使用 |
| BRPI0713963A2 (pt) | 2006-07-07 | 2012-11-27 | Novo Nordisk Healthcare Ag | conjugados de proteìna e métodos para sua preparação |
| CN101108895B (zh) * | 2006-07-19 | 2011-10-26 | 北京键凯科技有限公司 | 聚乙二醇乙醛衍生物及其与药物的结合物 |
| JP2010507382A (ja) | 2006-10-26 | 2010-03-11 | ノヴォ ノルディスク アクティーゼルスカブ | Ｉｌ−２１変異体 |
| CL2008002399A1 (es) * | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
| AU2008353850B2 (en) * | 2008-04-03 | 2014-08-21 | Biosteed Gene Expression Tech. Co., Ltd. | Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof |
| KR101104574B1 (ko) * | 2008-05-14 | 2012-01-11 | 성균관대학교산학협력단 | 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도 |
| UA104146C2 (ru) * | 2008-07-31 | 2014-01-10 | Фармаиссеншиа Корп. | ПОЛИМЕРНЫЕ КОНЪЮГАТЫ ФРАГМЕНТОВ ИНТЕРФЕРОНА-β, ЭРИТРОПОЭТИНА И ГОРМОНА РОСТА |
| KR20110039348A (ko) | 2008-08-06 | 2011-04-15 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질 |
| RU2409669C9 (ru) * | 2008-08-18 | 2012-05-27 | ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") | Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами |
| EP2331139B1 (en) * | 2008-09-11 | 2019-04-17 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
| AU2010207725B2 (en) | 2009-01-22 | 2015-06-11 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
| CN102612376A (zh) | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内功效的生长激素 |
| SI2512450T1 (en) | 2009-12-15 | 2018-05-31 | Ascendis Pharma Endocrinology Division A/S | A dry growth hormone composition transiently bound to a polymeric carrier |
| WO2011089255A1 (en) | 2010-01-22 | 2011-07-28 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
| RU2012134974A (ru) | 2010-01-22 | 2014-02-27 | Ново Нордиск Хелс Кеа Аг | Стабилизированное соединение гормона роста |
| EP2571896A4 (en) * | 2010-05-17 | 2014-01-08 | Cebix Inc | PEGYLATED C-PEPTIDE |
| EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
| EA019967B1 (ru) * | 2011-12-21 | 2014-07-30 | Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") | Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека |
| EP2981282B1 (en) | 2013-04-05 | 2020-11-04 | Novo Nordisk Health Care AG | Growth hormone compound formulation |
| ES2966888T3 (es) | 2014-11-06 | 2024-04-24 | Pharmaessentia Corp | Régimen de dosificación para el interferón pegilado |
| CA2978330C (en) * | 2015-03-11 | 2024-01-09 | Nektar Therapeutics | Conjugates of an il-7 moiety and a polymer |
| WO2017047788A1 (ja) | 2015-09-18 | 2017-03-23 | 国立大学法人宮崎大学 | 長時間作用型アドレノメデュリン誘導体 |
| CN114539384A (zh) * | 2020-11-19 | 2022-05-27 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇化长效生长激素及其制备方法和医药应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| ES2113354T3 (es) * | 1990-05-04 | 1998-05-01 | American Cyanamid Co | Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina. |
| WO1992016555A1 (en) * | 1991-03-18 | 1992-10-01 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| AU2147192A (en) * | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
| NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| PT1568772E (pt) * | 1995-09-21 | 2010-04-14 | Genentech Inc | Variantes da hormona do crescimento humana |
| AU751898B2 (en) * | 1997-07-14 | 2002-08-29 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| AU775937B2 (en) * | 1999-01-14 | 2004-08-19 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| EP1157037B1 (en) * | 1999-01-29 | 2003-07-30 | F. Hoffmann-La Roche Ag | Gcsf conjugates |
| AU2001289307A1 (en) * | 2000-04-06 | 2001-10-23 | Pharmacia Corporation | Chemically-modified myelopoietin conjugates |
| WO2002055532A2 (en) * | 2001-01-11 | 2002-07-18 | Maxygen Aps | Variant growth hormone molecules conjugated with macromolecular compounds |
-
2002
- 2002-11-20 CN CNA028259289A patent/CN1608079A/zh active Pending
- 2002-11-20 EA EA200400565A patent/EA008505B1/ru unknown
- 2002-11-20 EA EA200700431A patent/EA200700431A1/ru unknown
- 2002-11-20 IL IL16203102A patent/IL162031A0/xx unknown
- 2002-11-20 AU AU2002356990A patent/AU2002356990A1/en not_active Abandoned
- 2002-11-20 WO PCT/US2002/037270 patent/WO2003044056A2/en not_active Application Discontinuation
- 2002-11-20 CA CA002467731A patent/CA2467731A1/en not_active Abandoned
- 2002-11-20 GE GE5599A patent/GEP20063860B/en unknown
- 2002-11-20 KR KR1020047007708A patent/KR20050044858A/ko active IP Right Grant
- 2002-11-20 BR BRPI0214451-4A patent/BR0214451A/pt not_active IP Right Cessation
- 2002-11-20 AP APAP/P/2004/003050A patent/AP2004003050A0/en unknown
- 2002-11-20 RS YU53104A patent/RS53104A/sr unknown
- 2002-11-20 MX MXPA04004809A patent/MXPA04004809A/es not_active Application Discontinuation
- 2002-11-20 KR KR1020077011730A patent/KR20070072924A/ko not_active Application Discontinuation
- 2002-11-20 HU HU0500997A patent/HUP0500997A2/hu unknown
- 2002-11-20 EP EP02803695A patent/EP1453859A2/en not_active Withdrawn
- 2002-11-20 OA OA1200400143A patent/OA13063A/en unknown
- 2002-11-20 PL PL02374354A patent/PL374354A1/xx unknown
- 2002-11-20 JP JP2003545691A patent/JP2005525302A/ja active Pending
-
2004
- 2004-05-17 IS IS7268A patent/IS7268A/is unknown
- 2004-05-19 MA MA27686A patent/MA27544A1/fr unknown
- 2004-05-20 HR HR20040448A patent/HRP20040448A2/hr not_active Application Discontinuation
- 2004-05-20 CO CO04046633A patent/CO5580794A2/es not_active Application Discontinuation
- 2004-05-20 TN TNP2004000090A patent/TNSN04090A1/fr unknown
- 2004-05-20 ZA ZA200403907A patent/ZA200403907B/en unknown
- 2004-05-20 EC EC2004005114A patent/ECSP045114A/es unknown
- 2004-05-26 NO NO20042182A patent/NO20042182L/no not_active Application Discontinuation
-
2006
- 2006-07-14 JP JP2006193577A patent/JP2006321808A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RS53104A (en) | 2006-10-27 |
| WO2003044056A2 (en) | 2003-05-30 |
| TNSN04090A1 (fr) | 2006-06-01 |
| AU2002356990A1 (en) | 2003-06-10 |
| EA008505B1 (ru) | 2007-06-29 |
| MXPA04004809A (es) | 2004-08-11 |
| KR20050044858A (ko) | 2005-05-13 |
| JP2006321808A (ja) | 2006-11-30 |
| EA200700431A1 (ru) | 2008-02-28 |
| GEP20063860B (en) | 2006-06-26 |
| BR0214451A (pt) | 2006-05-30 |
| PL374354A1 (en) | 2005-10-17 |
| EP1453859A2 (en) | 2004-09-08 |
| WO2003044056A3 (en) | 2003-08-21 |
| IL162031A0 (en) | 2005-11-20 |
| HUP0500997A2 (en) | 2007-11-28 |
| ZA200403907B (en) | 2007-12-27 |
| CN1608079A (zh) | 2005-04-20 |
| EA200400565A1 (ru) | 2005-06-30 |
| CO5580794A2 (es) | 2005-11-30 |
| NO20042182L (no) | 2004-08-11 |
| KR20070072924A (ko) | 2007-07-06 |
| HRP20040448A2 (en) | 2006-02-28 |
| MA27544A1 (fr) | 2005-10-03 |
| JP2005525302A (ja) | 2005-08-25 |
| CA2467731A1 (en) | 2003-05-30 |
| IS7268A (is) | 2004-05-17 |
| OA13063A (en) | 2006-11-10 |
| ECSP045114A (es) | 2004-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2004003050A0 (en) | Chemically modified human growth hormone conjugates | |
| MXPA05004993A (es) | Conjugados de hormona del crecimiento humana modificados quimicamente. | |
| DK1715887T3 (da) | N-terminalt monopegyleret humant væksthormonkonjugater, fremgangsmåde til deres fremstilling og anvendelsen deraf | |
| MX344559B (es) | Compuestos de hormona de crecimiento humana recombinante unidos al peg. | |
| CA2594561C (en) | Formulations of human growth hormone comprising a non-naturally encoded amino acid | |
| TW200621291A (en) | Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof | |
| BG104070A (en) | Chimeric protein of interleukin-6, soluble receptor/ligand, its analogues and their application | |
| BG108499A (en) | A novel engineered superantigen for human therapy | |
| WO2004024097A8 (en) | Compositions and methods for the treatment of immune related diseases | |
| NL300830I1 (nl) | Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten | |
| AU4011300A (en) | Compositions and methods for the treatment of immune related diseases | |
| TNSN04235A1 (en) | Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone | |
| AU2001235761A1 (en) | Diagnosis of breast cancer using bcmp-11 as marker | |
| WO2001076639A3 (en) | Chemically-modified myelopoietin conjugates | |
| MXPA04000068A (es) | Conjugados de progenipoyetina modificados quimicamente. | |
| MXPA04001986A (es) | Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad. | |
| HUP0402334A2 (hu) | Módosított humán növekedési hormon | |
| WO2002099438A3 (en) | Modulation of steroid hormone uptake | |
| HK1082510A1 (en) | Promoter to il-18bp, its preparation and use | |
| DE60207257D1 (de) | Heterocarpin, ein protein, das humanes ghrh bindet | |
| TW200517125A (en) | Pharmaceutical composition for treatment of solid cancers | |
| WO2007005995A3 (en) | Compositions for buccal delivery of human growth hormone | |
| WO2002102849A3 (en) | Bcmp-101, a cancer associated protein |